BRIGHT MINDS BIOSCIENCES INC.
BRIGHT MINDS BIOSCIENCES INC. (DRUG): 8 pipeline candidates · 16 upcoming catalysts · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.10 · 0% dilution
Lead: Approved
8 candidates
16 upcoming, next in ~30d
0 buys · 1 sell (180d)
A transparent, data-derived signal for BRIGHT MINDS BIOSCIENCES INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$559.3M
Cash
$5.7M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| ammonia n 13 | Approved |
| BMB-101 | Phase 2 |
| esomeprazole magnesium | Approved |
| fludeoxyglucose f18 | Approved |
| guaifenesin | Approved |
| ibuprofen | Approved |
| loperamide | Approved |
| sodium fluoride f-18 | Approved |
Upcoming Catalysts (16)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
90
Total value held
$644.1M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 2,568,648 | $187.0M |
| perceptive advisors llc | 755,088 | $55.1M |
| blackrock, inc. | 621,933 | $45.4M |
| braidwell lp | 539,708 | $39.4M |
| adage capital partners gp, l.l.c. | 495,743 | $36.2M |
| driehaus capital management llc | 432,515 | $31.6M |
| balyasny asset management l.p. | 297,158 | $21.7M |
| deerfield management company, l.p. | 283,000 | $20.7M |
| ra capital management, l.p. | 265,000 | $19.3M |
| great point partners llc | 220,000 | $16.1M |
Showing top 10 of 90 institutional holders of BRIGHT MINDS BIOSCIENCES INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BRIGHT MINDS BIOSCIENCES INC.'s pipeline?
BRIGHT MINDS BIOSCIENCES INC. (DRUG) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BRIGHT MINDS BIOSCIENCES INC.'s lead drug candidate?
BRIGHT MINDS BIOSCIENCES INC.'s most advanced tracked candidate is ammonia n 13 (Approved) for 1 INDICATIONS AND USAGE Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease (1) ..
What is BRIGHT MINDS BIOSCIENCES INC.'s next catalyst?
BRIGHT MINDS BIOSCIENCES INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DUEXIS" — expected July 18, 2026.
What is BRIGHT MINDS BIOSCIENCES INC.'s market capitalization?
BRIGHT MINDS BIOSCIENCES INC.'s market capitalization is approximately $559.3M.
Who is the CEO of BRIGHT MINDS BIOSCIENCES INC.?
Mr. Ian McDonald is the chief executive officer of BRIGHT MINDS BIOSCIENCES INC. (DRUG).
Get the full picture on BRIGHT MINDS BIOSCIENCES INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.